Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Sep; 17(9):1272-82.

View in: PubMed

subject areas

Aged
Antineoplastic Agents
Biomarkers, Tumor
Carcinoma, Papillary
Female
Follow-Up Studies
Humans
Immunoenzyme Techniques
Indoles
Iodine Radioisotopes
Lymphatic Metastasis
Male
Middle Aged
Mutation
Neoplasm Staging
Prognosis
Proto-Oncogene Proteins B-raf
Radiation Tolerance
Salvage Therapy
Sulfonamides
Survival Rate
Thyroid Neoplasms

authors with profiles

Ezra Cohen